collegium pharmaceutical inc - COLL
COLL
Close Chg Chg %
47.13 -0.83 -1.76%
Open Market
46.30
-0.83 (1.76%)
Volume: 173.38K
Last Updated:
Dec 31, 2025, 1:15 PM EDT
Company Overview: collegium pharmaceutical inc - COLL
COLL Key Data
| Open $47.07 | Day Range 45.84 - 47.44 |
| 52 Week Range 23.23 - 50.79 | Market Cap $1.49B |
| Shares Outstanding 31.61M | Public Float 30.56M |
| Beta 0.61 | Rev. Per Employee N/A |
| P/E Ratio 30.80 | EPS $1.84 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 505.23K |
COLL Performance
| 1 Week | -5.44% | ||
| 1 Month | 0.96% | ||
| 3 Months | 36.17% | ||
| 1 Year | 64.50% | ||
| 5 Years | 135.30% |
COLL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About collegium pharmaceutical inc - COLL
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
COLL At a Glance
Collegium Pharmaceutical, Inc.
100 Technology Center Drive
Stoughton, Massachusetts 02072
| Phone | 1-781-713-3699 | Revenue | 631.45M | |
| Industry | Pharmaceuticals: Major | Net Income | 69.19M | |
| Sector | Health Technology | 2024 Sales Growth | 11.412% | |
| Fiscal Year-end | 12 / 2025 | Employees | 357 | |
| View SEC Filings |
COLL Valuation
| P/E Current | 30.796 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 15.431 |
| Price to Sales Ratio | 1.834 |
| Price to Book Ratio | 3.936 |
| Price to Cash Flow Ratio | 5.65 |
| Enterprise Value to EBITDA | 5.41 |
| Enterprise Value to Sales | 3.089 |
| Total Debt to Enterprise Value | 0.502 |
COLL Efficiency
| Revenue/Employee | 1,768,764.706 |
| Income Per Employee | 193,809.524 |
| Receivables Turnover | 2.763 |
| Total Asset Turnover | 0.45 |
COLL Liquidity
| Current Ratio | 0.947 |
| Quick Ratio | 0.877 |
| Cash Ratio | 0.369 |
COLL Profitability
| Gross Margin | 59.758 |
| Operating Margin | 30.297 |
| Pretax Margin | 15.61 |
| Net Margin | 10.957 |
| Return on Assets | 4.93 |
| Return on Equity | 32.616 |
| Return on Total Capital | 5.724 |
| Return on Invested Capital | 7.569 |
COLL Capital Structure
| Total Debt to Total Equity | 428.204 |
| Total Debt to Total Capital | 81.068 |
| Total Debt to Total Assets | 58.903 |
| Long-Term Debt to Equity | 399.427 |
| Long-Term Debt to Total Capital | 75.62 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Collegium Pharmaceutical Inc - COLL
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 276.87M | 463.93M | 566.77M | 631.45M | |
Sales Growth
| -10.69% | +67.56% | +22.17% | +11.41% | |
Cost of Goods Sold (COGS) incl D&A
| 127.99M | 252.34M | 240.60M | 254.10M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 68.94M | 134.39M | 149.26M | 169.16M | |
Depreciation
| 1.75M | 2.92M | 3.50M | 3.86M | |
Amortization of Intangibles
| 67.18M | 131.47M | 145.76M | 165.30M | |
COGS Growth
| -1.68% | +97.16% | -4.65% | +5.61% | |
Gross Income
| 148.88M | 211.59M | 326.17M | 377.34M | |
Gross Income Growth
| -17.21% | +42.12% | +54.15% | +15.69% | |
Gross Profit Margin
| +53.77% | +45.61% | +57.55% | +59.76% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 123.74M | 142.19M | 150.71M | 186.03M | |
Research & Development
| - | - | 7.71M | 1.30M | - |
Other SG&A
| 116.03M | 140.89M | 150.71M | 186.03M | |
SGA Growth
| +0.11% | +14.91% | +5.99% | +23.44% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 7.51M | 36.08M | 32.00M | 32.74M | |
EBIT after Unusual Expense
| 17.63M | 33.32M | 143.46M | 158.57M | |
Non Operating Income/Expense
| 12.00K | 1.05M | 15.62M | 13.98M | |
Non-Operating Interest Income
| 12.00K | 1.05M | 15.62M | 13.98M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 21.01M | 63.21M | 83.34M | 73.97M | |
Interest Expense Growth
| -27.24% | +200.81% | +31.84% | -11.24% | |
Gross Interest Expense
| 21.01M | 63.21M | 83.34M | 73.97M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (3.37M) | (28.85M) | 75.73M | 98.57M | |
Pretax Income Growth
| -112.23% | -754.98% | +362.53% | +30.15% | |
Pretax Margin
| -1.22% | -6.22% | +13.36% | +15.61% | |
Income Tax
| (74.89M) | (3.85M) | 27.58M | 29.38M | |
Income Tax - Current - Domestic
| 3.14M | 4.71M | 29.73M | 56.19M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (78.03M) | (8.55M) | (2.15M) | (26.81M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 71.52M | (25.00M) | 48.16M | 69.19M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 71.52M | (25.00M) | 48.16M | 69.19M | |
Net Income Growth
| +167.33% | -134.96% | +292.60% | +43.68% | |
Net Margin Growth
| +25.83% | -5.39% | +8.50% | +10.96% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 71.52M | (25.00M) | 48.16M | 69.19M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 71.52M | (25.00M) | 48.16M | 69.19M | |
EPS (Basic)
| 2.047 | -0.7391 | 1.4272 | 2.1438 | |
EPS (Basic) Growth
| +163.28% | -136.11% | +293.10% | +50.21% | |
Basic Shares Outstanding
| 34.94M | 33.83M | 33.74M | 32.27M | |
EPS (Diluted)
| 1.8563 | -0.7391 | 1.2933 | 1.8566 | |
EPS (Diluted) Growth
| +143.93% | -139.82% | +274.98% | +43.56% | |
Diluted Shares Outstanding
| 41.05M | 33.83M | 41.79M | 40.42M | |
EBITDA
| 94.08M | 203.79M | 324.72M | 360.47M | |
EBITDA Growth
| -20.17% | +116.63% | +59.34% | +11.01% | |
EBITDA Margin
| +33.98% | +43.93% | +57.29% | +57.09% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 46.80 | |
| Number of Ratings | 6 | Current Quarters Estimate | 1.659 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 8.013 | |
| Last Quarter’s Earnings | 2.18 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 7.478 | Next Fiscal Year Estimate | 6.113 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 5 | 4 |
| Mean Estimate | 1.66 | 1.78 | 8.01 | 6.11 |
| High Estimates | 1.79 | 1.86 | 10.08 | 8.12 |
| Low Estimate | 1.51 | 1.73 | 7.03 | 3.76 |
| Coefficient of Variance | 8.57 | 3.93 | 14.86 | 30.51 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 1 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Collegium Pharmaceutical Inc - COLL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Collegium Pharmaceutical Inc - COLL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 13, 2025 | John Gordon Freund Director | 23,129 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.36 per share | 794,712.44 |
| May 20, 2025 | Carlos V. Paya Director | 19,582 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 20, 2025 | Gino Santini Director | 85,447 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 25, 2025 | Colleen Tupper EVP & Chief Financial Officer | 156,667 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.03 per share | 4,704,710.01 |
| Mar 25, 2025 | Colleen Tupper EVP & Chief Financial Officer | 163,063 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30 per share | 4,891,890.00 |
| Mar 25, 2025 | Scott Dreyer EVP & Chief Commercial Officer | 103,613 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.03 per share | 3,111,498.39 |
| Mar 25, 2025 | Scott Dreyer EVP & Chief Commercial Officer | 122,494 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30 per share | 3,674,820.00 |
| Mar 7, 2025 | Shirley R. Kuhlmann EVP and General Counsel | 134,204 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.03 per share | 3,761,738.12 |
| Mar 7, 2025 | Shirley R. Kuhlmann EVP and General Counsel | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 7, 2025 | Shirley R. Kuhlmann EVP and General Counsel | 108,137 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.5 per share | 3,081,904.50 |
| Mar 7, 2025 | Shirley R. Kuhlmann EVP and General Counsel | 154,204 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.08 per share | 4,330,048.32 |
| Mar 7, 2025 | Shirley R. Kuhlmann EVP and General Counsel | 194,204 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.03 per share | 4,666,722.12 |
| Feb 13, 2025 | Thomas B. Smith EVP and Chief Medical Officer | 87,742 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.52 per share | 2,677,885.84 |
| Feb 13, 2025 | Thomas B. Smith EVP and Chief Medical Officer | 92,141 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.52 per share | 2,812,143.32 |
| Feb 13, 2025 | Thomas B. Smith EVP and Chief Medical Officer | 93,639 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2025 | Scott Dreyer EVP & Chief Commercial Officer | 169,376 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.52 per share | 5,169,355.52 |
| Feb 13, 2025 | Scott Dreyer EVP & Chief Commercial Officer | 147,706 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.52 per share | 4,507,987.12 |
| Feb 13, 2025 | Thomas B. Smith EVP and Chief Medical Officer | 88,326 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2025 | Michael Thomas Heffernan Director | 50,328 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 13, 2025 | Colleen Tupper EVP & Chief Financial Officer | 201,461 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $30.52 per share | 6,148,589.72 |